首頁 > 市場調查報告書 > 製藥

甲狀腺疾病治療市場規模、佔有率和成長分析（按類型、藥物、給藥途徑、分銷管道和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897672

甲狀腺疾病治療市場規模、佔有率和成長分析（按類型、藥物、給藥途徑、分銷管道和地區分類）－2026-2033年產業預測

Thyroid Gland Disorders Treatment Market Size, Share, and Growth Analysis, By Type (Hypothyroidism, Hyperthyroidism), By Drug (Levothyroxine, Liothyronine), By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，甲狀腺疾病治療市場規模將達到 27 億美元，到 2025 年將達到 28.1 億美元，到 2033 年將達到 38.5 億美元，在預測期（2026-2033 年）內，複合年成長率為 4%。

由於甲亢等疾病的盛行率不斷上升、人口老化、醫療技術的進步以及人們對早期診斷和治療意識提升，全球甲狀腺疾病治療市場正經歷顯著成長。個人化醫療和標靶治療的引入進一步豐富了市場格局，其中北美和歐洲由於患病率高和醫療支出高，佔據了相當大的市場佔有率。拉丁美洲和亞太地區的新興經濟體預計將因醫療基礎設施的改善和宣傳活動的開展而顯著成長。遠端醫療在內分泌諮詢和日常護理中的應用提高了醫療服務的可近性，尤其是在專科服務匱乏的地區。儘管診斷資源短缺和治療成本上升等挑戰可能會阻礙市場發展，但該市場的成長潛力仍然強勁。

甲狀腺疾病治療市場促進因素

全球甲狀腺疾病盛行率的不斷上升是推動治療方法需求成長的主要因素。隨著壓力水平的升高和生活方式的改變，甲狀腺功能亢進、甲狀腺機能低下症和甲狀腺癌等疾病的診斷率不斷提高。此外，環境因素也加劇了這些健康問題的快速成長。甲狀腺相關疾病的增加使得對有效治療方法和干涉措施的需求日益迫切，從而催生了一個不斷擴大的甲狀腺疾病治療市場。醫療保健和製藥公司正在積極響應這一領域日益成長的專業護理需求。

限制甲狀腺疾病治療市場的因素

甲狀腺疾病治療相關的經濟負擔是該市場面臨的一大阻礙因素。接受長期治療（例如放射性碘療法或手術）的患者往往需要承擔高昂的處方箋和手術費用。對於居住在醫療資源匱乏地區或缺乏足夠醫療保險的患者而言，這種經濟負擔尤其突出。因此，許多患者難以獲得所需的治療，最終限制了他們的選擇，並可能影響其整體治療效果。解決這些治療方法的可負擔性和可近性問題對於改善甲狀腺疾病患者的醫療服務至關重要。

甲狀腺疾病治療市場趨勢

由於全球甲狀腺疾病盛行率不斷上升，甲狀腺疾病治療市場正經歷顯著的變革時期。需求的激增促使市場相關人員致力於開發創新治療方法，以改善患者照護。製藥公司正大力投資研發，旨在推出更有效、更經濟且更符合個人需求的治療方法。隨著新療法的出現，製造商優先考慮改善患者預後，力求在提高患者生活品質的同時，最大限度地減少副作用。這一趨勢凸顯了各方致力於解決甲狀腺疾病複雜性的決心，並為持續的進步和治療方案的發展奠定了堅實的基礎。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

AbbVie Inc.（USA）
Amgen Inc.（USA）
GSK Plc（UK）
Merck KGaA（Germany）
Viatris Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
Exelixis Inc.（USA）
Abbott Laboratories（USA）
Fresenius SE & Co. KGaA（Germany）
Jerome Stevens Pharmaceuticals Inc.（USA）
Lannett Co. Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35J2083

Thyroid Gland Disorders Treatment Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.81 Billion in 2025 to USD 3.85 Billion by 2033, growing at a CAGR of 4% during the forecast period (2026-2033).

The global thyroid gland disorders treatment market is experiencing significant growth, driven by an increase in prevalent conditions like hyperthyroidism, an aging population, advancements in medical technology, and heightened awareness regarding early diagnosis and treatment. The introduction of personalized medicine and targeted therapies further enriches the market landscape, with North America and Europe holding substantial share due to higher incidence rates and healthcare expenditure. Emerging economies in Latin America and Asia-Pacific are poised for notable growth, supported by improved healthcare infrastructures and awareness initiatives. The adoption of telemedicine for endocrinology consultations and routine care enhances accessibility, especially where specialist services are scarce. Challenges, such as limited diagnostic resources and high treatment costs, may hinder progress, yet the market's potential growth remains robust.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The rising prevalence of thyroid disorders globally is significantly driving the demand for treatment options. Conditions such as hyperthyroidism, hypothyroidism, and thyroid cancer are increasingly being diagnosed, largely due to heightened stress levels and lifestyle changes affecting individuals. Furthermore, environmental factors have contributed to the surge in these health issues. This growing incidence of thyroid-related ailments has created an urgent need for effective therapies and interventions, leading to an expansion in the market dedicated to treating thyroid gland disorders. Healthcare providers and pharmaceutical companies are responding to the escalating requirement for specialized medical care in this area.

Restraints in the Thyroid Gland Disorders Treatment Market

The financial burden associated with thyroid gland disorder treatments poses a significant restraint in this market. Patients undergoing long-term therapies, such as radioactive iodine treatments or surgical interventions, often face substantial costs for their prescriptions and procedures. This financial strain can be particularly pronounced for individuals in underserved regions or those without adequate health insurance coverage. Consequently, many patients may experience challenges in accessing necessary treatments, ultimately limiting their options and impacting overall patient outcomes. Addressing the affordability and accessibility of these treatment modalities is crucial for improving care for those affected by thyroid disorders.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing a significant transformation driven by increasing incidence rates worldwide. This surge in demand has prompted market players to focus on developing innovative treatment options that enhance patient care. Pharmaceutical companies are investing heavily in research and development, aiming to introduce more effective and affordable therapies tailored to individual needs. As new treatment modalities emerge, manufacturers are prioritizing improved patient outcomes, seeking to enhance quality of life while minimizing adverse effects. This trend underscores a commitment to addressing the complexities of thyroid disorders, fostering a robust landscape for ongoing advancements and therapeutic solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2026-2033)

Market Overview
Hypothyroidism
Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2026-2033)

Market Overview
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based compounds
Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous
Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Wholesale Distribution
Retail Stores
Online Pharmacy
Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2026-2033)

North America (Type, Drug, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Type, Drug, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jerome Stevens Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lannett Co. Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments